Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 956 participants.

Also called NCT07653477

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 956 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07653477
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07653477. Randomized; no masking; primary purpose treatment. Start 2026-09-07 (actual); primary completion 2028-02-29 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
Acronym
UNIGUIDE-2
Intervention (Drug)
UBT251 Injection 2.0 mg group
Intervention (Drug)
UBT251 Injection 4.0 mg group
Intervention (Drug)
UBT251 Injection 6.0 mg group
Intervention (Drug)
Semaglutide Injection
Lead sponsor
The United Bio-Technology (Hengqin) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07653477
Content hash
4bff62d8281c6fccb1b67f3365aaa6b0f25d5c05bf43fea1c6c4f8e3c10c2aa5